51
|
Bourdais R, Troussier I, Epaillard N, Chauffert-Yvart L, Gérard M, Sargos P, Riet FG, Canova CH, Jenny C, Culot F, Le Corre E, Ozsahin M, Huguet F, Bachet JB, Simon JM, Maingon P, Blais E. Chimioradiothérapie des cancers du pancréas : pourquoi et comment protéger la rate ? Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
52
|
Epaillard N, Troussier I, Bourdais R, Hammoudi N, Huguet F, Bachet JB, Vaillant JC, Thierry A, Gligorov J, Ozsahin M, Spano JP, Simon JM, Maingon P, Blais E. Faut-il adapter la chimioradiothérapie néoadjuvante des cancers de l’œsophage à l’histologie ? Analyse des essais de phase III. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
53
|
Chevalier A, Riet FG, Feuvret L, Canova CH, Blais E, Larpin F, Jolivet I, Granger B, Maingon P. Évaluation de la prévalence et de la prise en charge de la douleur sur le plateau technique du service de radiothérapie des hôpitaux universitaires Pitié-Salpêtrière-Charles-Foix. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
54
|
Troussier I, Klausner G, Blais E, Giraud P, Lahmi L, Pflumio C, Faivre JC, Geoffrois L, Babin E, Morinière S, Maingon P, Thariat J. Évolutions dans la prise en charge des métastases ganglionnaires cervicales sans cancer primitif retrouvé : doses et volumes cibles de la radiothérapie avec modulation d’intensité. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
55
|
Chargari C, Maingon P, Mornex F, Haie-Méder C. La curiethérapie : la plus ancienne des techniques modernes d’irradiation. Cancer Radiother 2018; 22:303-304. [DOI: 10.1016/j.canrad.2017.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Accepted: 12/19/2017] [Indexed: 11/25/2022]
|
56
|
Troussier I, Klausner G, Blais E, Giraud P, Lahmi L, Pflumio C, Faivre JC, Geoffrois L, Babin E, Morinière S, Maingon P, Thariat J. [Advances in the management of cervical lymphadenopathies of unknown primary with intensity modulated radiotherapy: Doses and target volumes]. Cancer Radiother 2018; 22:438-446. [PMID: 29731331 DOI: 10.1016/j.canrad.2017.10.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 10/24/2017] [Indexed: 11/16/2022]
Abstract
The definition of nodal and/or mucosal target volumes for radiation therapy for lymphadenopathies of unknown primary is controversial. Target volumes may include all nodal areas bilaterraly and be pan-mucosal or unilateral, selective, including the sole oropharyngeal mucosa. This review presents current recommendations in light of changes in the TNM classification, Human papillomavirus status and therapeutic advances. We conducted a systematic review of the literature with the following keywords: lymphadenopathy; head and neck; unknown primary and radiation therapy. There are no direct comparative studies between unilateral or bilateral nodal irradiation or pan-mucosal and selective mucosal irradiation. Contralateral lymph node failure rates range from 0 to 6% after unilateral nodal irradiation and 0 and 31% after bilateral irradiation. Occurrence of a mucosal primary varies between 0 and 19.2%. Initial clinical presentation and Human papillomavirus status are critical to define mucosal target volumes. Intensity-modulated radiotherapy is recommended (rather than three-dimensional irradiation) to avoid toxicities. Systemic treatments have similar indications as for identified primary head and neck cancers. Failures do not appear superior in case of unilateral nodal irradiation but comparative studies are warranted due to major biases hampering direct comparisons. Human papillomavirus status should be incorporated into the therapeutic strategy and practice-changing TNM staging changes will need to be evaluated.
Collapse
|
57
|
Lahmi L, Idbaih A, Canova C, Jacob J, Kaczmarek E, Fenioux C, Capelle L, Troussier I, Maingon P, Feuvret L. EP-1198: Whole brain radiotherapy and concurrent temozolomide in multifocal newly diagnosed glioblastoma. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31508-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
58
|
Reynaud T, Bertaut A, Desandes C, Ahossi V, Zwetyenga N, Duvillard C, Folia M, Vulquin N, Crehange G, Maingon P. EP-1164: Bone and dental complications in patients with head and neck cancer treated with IMRT. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31474-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
59
|
Blais E, Huertas A, Ozsahin M, Créhange G, Huguet F, Bourhis J, Maingon P, Antoine M, Troussier I. PO-0784: Contemporary esophageal cancer management by chemo radiation: survey of French radiation oncologists. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31094-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
60
|
Rochand A, Tankere F, Jacob J, Herman P, Maingon P, Feuvret L. EP-1174: Outcomes in patients with cervical paragangliomas treated with intensity-modulated radiotherapy. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31484-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
61
|
Schernberg A, Rivin del Campo E, Rousseau B, Matzinger O, Loi M, Maingon P, Huguet F. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. Clin Transl Radiat Oncol 2018; 10:13-22. [PMID: 29928701 PMCID: PMC6008627 DOI: 10.1016/j.ctro.2018.02.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Revised: 02/27/2018] [Accepted: 02/27/2018] [Indexed: 02/07/2023] Open
Abstract
An estimated 990,000 new cases of gastric cancer are diagnosed worldwide each year. Surgical excision, the only chance for prolonged survival, is feasible in about 20% of cases. Even after surgery, the median survival is limited to 12 to 20 months due to the frequency of locoregional and/or metastatic recurrences. This led to clinical trials associating surgery with neoadjuvant or adjuvant treatments to improve tumor control and patient survival. The most studied modalities are perioperative chemotherapy and adjuvant chemoradiotherapy. To date, evidence has shown a survival benefit for postoperative chemoradiotherapy and for perioperative chemotherapy. Phase III trials are ongoing to compare these two modalities. The aim of this review is to synthesize current knowledge about adjuvant chemoradiotherapy in the management of gastric adenocarcinoma, and to consider its prospects by integrating modern radiotherapy techniques.
Collapse
Key Words
- 5FU, 5-fluorouracil
- 5FU-LV, 5-fluorouracil leucovorin
- Adenocarcinoma
- Adjuvant therapy
- CRT, chemoradiotherapy
- CT, chemotherapy
- Chemoradiotherapy
- DCF, Doxorubicin Cisplatin 5-fluorouracil
- ECF, Epirubicin Cisplatin 5-fluorouracil
- ECX, Epirubicin Cisplatin Capecitabin
- FOLFOX, 5-fluorouracil oxaliplatin
- FUFOL, bolus 5-fluorouracil followed by leucovorin over 15 minutes
- Gastric cancer
- IMRT
- IMRT, intensity modulated radiation therapy
- LV, leucovorin
- RT, radiation therapy
- XELOX, capecitabin oxaliplatine
Collapse
|
62
|
Klausner G, Troussier I, Feuvret L, Jacob J, Simon JM, Malouf G, Canova CH, Lamproglou I, Borius PY, Valéry C, Rouprêt M, Cornu P, Mazeron JJ, Spano JP, Maingon P. Étude rétrospective monocentrique de la prise en charge des métastases cérébrales de cancer du rein. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
63
|
Chea M, Verrecchia E, Jacob J, Troussier I, Feuvret L, Borius PY, Cuttat M, Valéry CA, Mazeron JJ, Maingon P, Jenny C. Arcthérapie conformationnelle mono-isocentrique des métastases cérébrales multiples : planification automatisée et comparaison dosimétrique avec le Gammaknife ® Perfexion™. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
64
|
Rochand A, Tankéré F, Jacob J, Herman P, Mazeron JJ, Maingon P, Feuvret L. Résultats de la radiothérapie conformationnelle avec modulation d’intensité chez les patients atteints de paragangliomes craniocervicaux. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
65
|
Blais E, Pichon B, Mampuya A, Antoine M, Lagarde P, Kantor G, Breton-Callu C, Lefebvre C, Gerard M, Aamarcha A, Ozsahin M, Bourhis J, Maingon P, Troussier I, Pourel N. Doses aux organes à risque en radiothérapie conformationnelle et en radiothérapie stéréotaxique : les poumons. Cancer Radiother 2017; 21:584-596. [DOI: 10.1016/j.canrad.2017.07.046] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 07/21/2017] [Accepted: 07/23/2017] [Indexed: 12/25/2022]
|
66
|
Blais E, Sargos P, Kantor G, Huertas A, Bécouarn Y, Fonck-Frayssinet M, Béchade D, Evrard S, Ozsahin E, Créhange G, Huguet F, Bourhis J, Maingon P, Troussier I. Prise en charge des patients atteints d’un cancer de l’œsophage par chimioradiothérapie : enquête de pratique nationale multicentrique. Cancer Radiother 2017. [DOI: 10.1016/j.canrad.2017.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
67
|
Maingon P, Simon JM, Canova CH, Troussier I, Besson N, Caillot É, Huguet F. [Clinical research for rectal carcinoma: State of the art and objectives]. Cancer Radiother 2017; 21:533-535. [PMID: 28890092 DOI: 10.1016/j.canrad.2017.07.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2017] [Accepted: 07/18/2017] [Indexed: 11/27/2022]
Abstract
The treatment of rectal carcinoma is based on multidisciplinary strategy and multimodal approaches including gastrointestinal tract specialists, medical oncologists, radiation oncologists and surgery. The different objectives should be declined according to the characteristics of the tumours. The aim of the therapist would be to select the best strategy offering to the patient to be cured with as less as possible late adverse toxicity. The challenge of the treatment of small tumours is to maintain a functional anal sphincter while minimizing the risk of local recurrence. The standard treatment of locally advanced disease is aiming firstly to cure the patient and secondly to prevent late complications. Each of these clinical presentations of the disease has to be considered as a whole taking into account the new surgical techniques and a personalized approach adapted to the tumour. Nowadays they should be studied with dedicated clinical trials.
Collapse
|
68
|
Klausner G, Troussier I, Malouf G, Feuvret L, Jacob J, Simon JM, Canova C, Lamproglou I, Borius PY, Valery C, Cornu P, Rouprêt M, Mazeron JJ, Spano JP, Maingon P. A retrospective study of the management of metastatic renal cell carcinoma brain tumors. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
69
|
Gobert A, Jaeger A, Taillade L, Osman N, Lassoued D, Mateescu C, Maingon P, Tilleul P, Spano JP, Bellanger A. Anti-PD1 inhibitors: Assessment of proper use, efficacy and economic impact in daily practice. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx375.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
70
|
Maingon P, Mirjolet C, Truc G, Karine P, Nöel G, Thariat J, Le Pechoux C, Sargos P, Marchal C, Blay J, Salas S, Delannes M, Lagrange J, Mahé M, Coindre J, Collin F, Chibon F, Grisi C, Gauthier M, Merlin J. Sarcoma in irradiated area (SARI): radiation-induced CD8 T-lymphocytes apoptosis as a potential predisposition factor: results of the SARI trial. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30576-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
71
|
Cerda T, Martin É, Truc G, Créhange G, Maingon P. Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma. Cancer Radiother 2016; 21:16-20. [PMID: 28041814 DOI: 10.1016/j.canrad.2016.07.102] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Accepted: 07/04/2016] [Indexed: 11/17/2022]
Abstract
PURPOSE Spermatic cord sarcoma is a rare disease, which management remains controversial due to the lack of guidelines. The standard therapeutic approach is surgical: wide soft-tissue resection with radical inguinal orchidectomy, The diagnosis is made during the analysis of the specimen. The high rate of local recurrence indicates adjuvant radiotherapy of the tumor bed. The aim of this series is to determine the efficacy and safety of postoperative intensity-modulated radiotherapy for spermatic cord sarcomas. PATIENTS AND METHODS Our series included five consecutive cases of spermatic cord sarcoma treated between 2011 and 2014. The indications for radiotherapy were: R1 status after initial surgery, R1 status after wide en bloc resection and orchiectomy, high French federation of cancer centers (FNCLCC) grade, tumor size over 5cm, tumor resection during surgery. RESULTS Median age at diagnosis was 66years (range 46-84years). Median follow-up was 18months (range 6-28months). Four patients had repeat surgery after incomplete removal. All surgeries were orchidectomy with primary ligation of testicular vessels. One patient did not have an in sano margin after the second surgical procedure. The median tumor size was 60mm (range 30-150mm). No recurrence was observed during the follow-up. CONCLUSION No grade 4 toxicities were reported and the most frequent acute toxicity was dermatitis. No recurrence was reported after adjuvant intensity-modulated radiotherapy. The treatment is feasible and well tolerated and seems to provide encouraging results regarding locoregional control of the disease. Dynamic or rotational intensity-modulated radiotherapy is now recommended to decrease acute toxicities while improving the efficacy of this approach.
Collapse
|
72
|
Pasquier D, Peiffert D, Maingon P, Pommier P, Martinage G, Nickers P, Tresch E, Lacornerie T, Lartigau É. Phase II multicentrique de complément d’irradiation stéréotaxique hypofractionnée pour le cancer prostatique de risque intermédiaire. Cancer Radiother 2016. [DOI: 10.1016/j.canrad.2016.07.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
73
|
Thariat J, Sun X, Tao Y, Maingon P, Deloge SR, Huguet F, Wiazzane N, Franck D, Bollet M, Chapet S, Bosset M, Guichard F, Alfonsi M, Phare O, Gaudaire S, Vulquin N, Rouvier J, Michel C, Bourhis J. Quality Assurance (QA) of Randomized Phase 2 GORTEC Trial 2014-04 of Stereotactic Irradiation in Patients With Oligometastatic Squamous Cell Carcinomas of the Head and Neck. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
74
|
Maingon P. Argumentaire clinique pour la radiothérapie guidée par imagerie par résonance magnétique. Cancer Radiother 2016; 20:558-63. [DOI: 10.1016/j.canrad.2016.07.070] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Revised: 07/12/2016] [Accepted: 07/13/2016] [Indexed: 11/24/2022]
|
75
|
TAO Y, Aupérin A, Graff P, Gregoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Bardet E, Rives M, Geoffrois L, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Sire C, Bourhis J. Concurrent Chemoradiation Therapy Versus Acceleration of Radiation Therapy With or Without Concurrent Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): 7-Year Survival Data From a Phase 3 Randomized Trial and Prognostic Factors. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|